Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes rather than financial performance.
Material Changes
On April 16, 2015, specific Directors and PDMRs increased their interests in American Depositary Shares (ADSs) at a price of $47.73 per ADS. These increases resulted from the re-investment of dividends paid to shareholders on April 9, 2015.
- Dr M M Slaoui: 1,670.294 ADSs
- Mr W C Louv: 158.002 ADSs
- Mr N Hirons: 236.356 ADSs
- Mr D E Troy: 1,139.208 ADSs
- Dr K Slaoui (Connected Person): 76.122 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the dividend reinvestment plan details for the April 9, 2015 payment.
- Confirm the market price of GSK ADSs on April 16, 2015 ($47.73).
- Review the total shareholding positions of the listed Directors and PDMRs following these transactions.